A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

Combination Therapy ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Sexually Active ◽

Urinary Tract Symptoms ◽

The Impact ◽

Re: A Prospective Randomised Placebo-Controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)

The Journal of Urology ◽

10.1097/01.ju.0000554112.39991.bd ◽

2019 ◽

Vol 201 (5) ◽

pp. 833-834

Author(s):

Steven A. Kaplan

Keyword(s):

Urinary Tract ◽

Combination Therapy ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Sexually Active ◽

Urinary Tract Symptoms ◽

The Impact ◽

Re: A Prospective Randomised Placebo-controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)

European Urology ◽

10.1016/j.eururo.2018.10.034 ◽

2019 ◽

Vol 75 (2) ◽

pp. 344-345 ◽

Cited By ~ 1

Author(s):

Ignacio Moncada ◽

Pramod Krishnappa

Keyword(s):

Urinary Tract ◽

Combination Therapy ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Sexually Active ◽

Urinary Tract Symptoms ◽

The Impact ◽

Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms ( LUTS ) secondary to benign prostatic hyperplasia ( BPH ): A post hoc analysis of a prospective randomised placebo‐controlled study

International Journal of Clinical Practice ◽

10.1111/ijcp.13282 ◽

2018 ◽

Vol 73 (9) ◽

pp. 1-9 ◽

Cited By ~ 5

Author(s):

Raymond C. Rosen ◽

Claus G. Roehrborn ◽

Michael J. Manyak ◽

Juan Manuel Palacios‐Moreno ◽

Timothy H. Wilson ◽

...

Keyword(s):

Urinary Tract ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Sexually Active ◽

Post Hoc Analysis ◽

Urinary Tract Symptoms ◽

Post Hoc ◽

The Impact ◽

1096 Combination therapy with finasteride and tadalafil once daily for 6 months: A randomized, placebo-controlled study in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

European Urology Supplements ◽

10.1016/s1569-9056(13)61571-7 ◽

2013 ◽

Vol 12 (1) ◽

pp. e1096-e1097 ◽

Cited By ~ 2

Author(s):

A.R. Casabe ◽

C. Roehrborn ◽

Pozza L.F. Da ◽

S. Zepeda ◽

R. Henderson ◽

...

Keyword(s):

Urinary Tract ◽

Combination Therapy ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Once Daily ◽

Urinary Tract Symptoms ◽

Faculty Opinions recommendation of Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725968810.793564004 ◽

2019 ◽

Author(s):

Alexis Te

Keyword(s):

Water Vapor ◽

Urinary Tract ◽

Minimally Invasive ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Randomized Controlled ◽

Urinary Tract Symptoms ◽

Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)

Inflammopharmacology ◽

10.1007/s10787-017-0343-2 ◽

2017 ◽

Vol 25 (4) ◽

pp. 451-458

Author(s):

Alireza Ghadian ◽

Mehran Rezaei

Keyword(s):

Fatty Acids ◽

Urinary Tract ◽

Combination Therapy ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Urinary Tract Symptoms ◽

Estimating The Economic Benefit Of Treatment With Alpha-Blocker Plus Antimuscarinic As A Fixed-Dose Combination (FDC) Tablet Versus Concomitant Combination Therapy (CCT) In Men With Lower Urinary Tract Symptoms (Luts) Associated With Benign Prostatic Hyperplasia (BPH)

Value in Health ◽

10.1016/j.jval.2017.08.515 ◽

2017 ◽

Vol 20 (9) ◽

pp. A489-A490

Author(s):

S Bowditch ◽

C McCrea ◽

E Arbe ◽

J Nazir

Keyword(s):

Urinary Tract ◽

Combination Therapy ◽

Economic Benefit ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Fixed Dose ◽

Urinary Tract Symptoms ◽

Dose Combination ◽

Combination Therapy With Doxazosin and Finasteride for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptoms and a Baseline Total Prostate Volume of 25 Ml or Greater

The Journal of Urology ◽

10.1097/00005392-200601000-00058 ◽

2006 ◽

Vol 175 (1) ◽

pp. 217???221 ◽

Cited By ~ 2

Author(s):

Steven A. Kaplan ◽

John D. McConnell ◽

Claus G. Roehrborn ◽

Alan G. Meehan ◽

Michael W. Lee ◽

...

Keyword(s):

Urinary Tract ◽

Combination Therapy ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Prostate Volume ◽

Prostatic Hyperplasia ◽

Urinary Tract Symptoms ◽

Double-blind randomized placebo-controlled study of bixa orellana in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia

International braz j urol ◽

10.1590/s1677-55382007000400006 ◽

2007 ◽

Vol 33 (4) ◽

pp. 493-501 ◽

Cited By ~ 11

Author(s):

Luis Zegarra ◽

Abraham Vaisberg ◽

Cesar Loza ◽

Roxana L. Aguirre ◽

Miguel Campos ◽

...

Keyword(s):

Urinary Tract ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Bixa Orellana ◽

Double Blind ◽

Urinary Tract Symptoms ◽

Re: A Placebo-Controlled Study Investigating the Efficacy and Safety of the Phosphodiesterase Type 5 Inhibitor UK-369,003 for the Treatment of Men With Lower Urinary Tract Symptoms Associated With Clinical Benign Prostatic Hyperplasia

The Journal of Urology ◽

10.1016/j.juro.2011.09.107 ◽

2012 ◽

Vol 187 (1) ◽

pp. 213-214

Author(s):

Steven A. Kaplan

Keyword(s):

Urinary Tract ◽

Lower Urinary Tract ◽

Prostatic Hyperplasia ◽

Controlled Study ◽

Efficacy And Safety ◽

Phosphodiesterase Type 5 Inhibitor ◽

Urinary Tract Symptoms ◽

Phosphodiesterase Type ◽